SPONSOR
Chinese PLA General Hospital
Total Trials
13
Recruiting
13
Phases
Phase 1, Phase 2, Phase 2, Phase 1
Conditions studied: Papillary Thyroid CancerParkinson DiseaseHodgkin's LymphomaNon-Hodgkin's LymphomaDiabetic Nephropathy Type 2Diabetic Kidney DiseaseType 2 DiabetesGastric AdenocarcinomaBenign Prostatic Hyperplasia (BPH)Hematopoietic Stem Cell Transplantation
Chinese PLA General Hospital is a clinical research sponsor with 13 registered studies on ClinicalTrials.gov, of which 13 are actively recruiting participants. Research covers conditions including Papillary Thyroid Cancer, Parkinson Disease, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma.
The trial portfolio spans Phase 1, Phase 2, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Chinese PLA General Hospital
How many clinical trials has Chinese PLA General Hospital sponsored?
ClinicalMetric currently tracks 13 clinical trials sponsored by Chinese PLA General Hospital, of which 13 are actively recruiting participants. These trials cover conditions including Papillary Thyroid Cancer, Parkinson Disease, Hodgkin's Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Chinese PLA General Hospital research focus on?
Chinese PLA General Hospital clinical trials span Papillary Thyroid Cancer, Parkinson Disease, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Diabetic Nephropathy Type 2, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Chinese PLA General Hospital clinical trial?
To participate in a Chinese PLA General Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Chinese PLA General Hospital trials with current recruitment status updated daily.
Clinical Trials by Chinese PLA General Hospital
NCT06733740
Recruiting
Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma
Papillary Thyroid Cancer
NCT07044973
Recruiting
VIM+PTT MRgFUS for PD
Parkinson Disease
NCT02259556 Phase 1, Phase 2
Recruiting
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Hodgkin's Lymphoma
NCT05888909
Recruiting
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Diabetic Nephropathy Type 2
NCT06798376
Recruiting
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer
Gastric Adenocarcinoma
NCT06817733
Recruiting
Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging
Benign Prostatic Hyperplasia (BPH)
NCT07791576 Phase 2
Recruiting
Population PK-guided ATG Dosing in Haplo-HSCT
Hematopoietic Stem Cell Transplantation
NCT05738525
Recruiting
Comparative Study of Prognosis and QOL Between APD-RPM and CAPD
End-stage Renal Disease
NCT07762664
Recruiting
Photon-Counting CT Versus Conventional CT for Carotid Plaque Assessment in Patients With Carotid Artery Stenosis
Carotid Artery Stenosis
NCT06729762
Recruiting
Ultrasound-guided Thermal Ablation for Benign Thyroid Nodules
Thyroid Nodule (Benign)
NCT06393361 Phase 2
Recruiting
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
NCT07775508 Phase 1
Recruiting
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
B-cell Lymphoma
NCT06954740 Phase 2
Recruiting
Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury
Acute Kidney Injury
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology